 tavr acceler nearli ep
guid rais reiter outperform top
pick ew rais target price
end high note grow nearli appear
momentum carri well management see broad-bas demand across
indic new tavr center contribut growth
rise year-end deliv averag growth
past quarter strength us tavr follow strong superior result
low-risk tavr present march look less like bolu like trend
reiter outperform rate ew remain one two larg cap top pick
rais target price
ep includ impact acceler spend drove
shortfal estim management reinvest upsid acceler
invest market develop clinic field rep support rise demand given
larg expand tavr market address undertr indic
cancer-lik mortal risk therapeut altern expect invest
drive return leverag time ew drive adopt tavr global
ep guid tavr total sale expect around top end rang
management rais ep guidanc management rais bottom-end
total sale tavr guidanc bil bil respect
expect result around top end guidanc tavr total sale
guid estim consensu sale ep
rais estim sale ep weve rais estim
project sale bil bil organ ep
valuat target price base ev/ebitda multipl
unchang bil ebitda estim unchang risk product delay
unexpect share loss potenti litig regulatory/qu issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
global manufactur provid
medic devic equip structur valvular heart diseas
critic care
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv growth
high-growth segment grow growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda grey
scenario base emerg segment deliv growth
high-growth segment grow growth grow
 close
addit detail takeaway
compani estim grew in-lin ww tavr growth remain stabl
compani continu exercis price disciplin ew tavr sale
in-lin tavr procedur growth driven step-up tavr treatment
follow strong clinic trial data tavr growth also broad-
base across center ou tavr procedur grew high-teen compani
growth compar europ ew tavr procedur grew mid-teen compani
share stabl tavr uptak continu strong countri therapi penetr
still low launch sapien ultra on-going eu compani expect
underli tavr sale around top rang sale bil
expect growth rate lower year progress
tmtt mitral tricuspid program continu progress
tmtt sale mil neg impact voluntari pascal field correct action
complet quarter compani continu enrol patient
clasp pivot trial studi pascal patient primari degen mitral valv
diseas track complet enrol end year recal compani
receiv approv enrol patient clasp secondari mitral valv diseas pivot trial
patient function mitral diseas ew continu enrol patient trial
mitral replac compani expect begin enrol sapien pivot trial
tricuspid repair compani begun enrol clasp iitr symptomat
sever tricuspid regurgit trial compani expect tmtt sale mil
sale declin result lower surgic aortic valv procedur tavr
adopt increas partial off-set continu strong adopt compani premium
technolog ew inspiri surgic aortic valv continu growth driver late
compani also receiv european regulatori approv harpoon beat heart mitral valv
repair system process begin commerci launch compani
expect sale mil
sale y/i exclud casm acquisit underli casm sale
mil perform quarter driven demand hemospher
advanc monitor platform continu adopt smart recoveri compani also
initi commerci launch foresight tissu oximetri sensor integr
hemospher monitor platform compani expect sale mil
compani rais bottom-end sale rang bil
bil expect full-year underli sale growth rate around top
rang compani also rais bottom-end tavr sale rang bil
bil expect tavr underli full-year sale growth rate around top
rang ep guidanc also rais fx
expect neg impact sale mil compani
expect sale bill ep
 op margin bp estim
bottom line sale net cog lower tax rate partial off-set
higher sg higher non-op deliv ep penni
estim higher expect sg driven increas field clinic personnel
support tavr case tmtt case europ well initi relat
diseas awar therapi adopt gross margin bp y/i
driven spend support new european medic devic regul one-tim
cost associ move cardioband product israel ireland partial off-set
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto januari
chang model
increas sale estim ep estim
also made minor adjust top-lin project beyond increas
sale estim per year averag outer year ep estim rise
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
